SCHEMBL14691027

SCHEMBL14691027

C[N+](C)(C)CCOP(=O)([O-])Oc1ccccc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
AKT1 P31749 2/20 0.43
ESR1 P03372 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CDC25A P30304 1/20 0.43
AGTR1 P30556 1/20 0.43
ADRA1A P35348 1/20 0.43
KCNH2 Q12809 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 4/20 0.37
RECQL P46063 1/20 0.37
ADRA2B P18089 1/20 0.36
PTGS1 P23219 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PRKD3 O94806 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8641241 0.84 LMNA (0.44) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL3395881 0.83 SRC (0.38) LMNACYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL1263901 0.83 LMNA (0.43) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL1085919 0.81 HTT (0.44) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL2912361 0.80 NPC1 (0.48) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL8154893 0.79 LMNA (0.47) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL2825992 0.77 LMNA (0.45) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL30681640 0.75 ALDH1A1 (0.44) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL12844852 0.73 CYP1A2 (0.61) LMNAESR1KCNH2CYP1A2CYP2C9
SCHEMBL19244145 0.72 LMNA (0.46) LMNAAKT1ESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119997981-A Particulate compositions comprising peptides and uses thereof 塔西亚制药公司 2025-05-13 CN disclosed
US-20210238311-A1 ANTIBODIES AGAINST PHOSPHORYLCHOLINE ATHERA BIOTECHNOLOGIES AB (SE) 2021-08-05 US disclosed
US-20210230310-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES ATHERA BIOTECHNOLOGIES AB (SE) 2021-07-29 US disclosed
EP-2742068-B1 NEW ANTIBODIES AGAINST PHOSPHORYLCHOLINE ATHERA BIOTECHNOLOGIES AB (SE) 2019-04-03 EP disclosed
US-20180086848-A1 ANTIBODIES AGAINST PHOSPHORYLCHOLINE ATHERA BIOTECHNOLOGIES AB (SE) 2018-03-29 US disclosed
US-20180086847-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES ATHERA BIOTECHNOLOGIES AB (SE) 2018-03-29 US disclosed
US-9803028-B2 Antibodies against phosphorylcholine ATHERA BIOTECHNOLOGIES AB (SE) 2017-10-31 US disclosed
US-9796786-B2 Antibodies binding to phosphorylcholine (PC) and/or PC conjugates ATHERA BIOTECHNOLOGIES AB (SE) 2017-10-24 US disclosed
US-20140193413-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES DYAX CORP. (US) 2014-07-10 US disclosed
US-20140178410-A1 ANTIBODIES AGAINST PHOSPHORYLCHOLINE DYAX CORP. (US) 2014-06-26 US disclosed
EP-2742068-A1 NEW ANTIBODIES AGAINST PHOSPHORYLCHOLINE Athera Biotechnologies AB (SE) 2014-06-18 EP disclosed
EP-2741770-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES Athera Biotechnologies AB (SE) 2014-06-18 EP disclosed
WO-2013022968-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES ATHERA BIOTECHNOLOGIES AB (SE) 2013-02-14 WO disclosed
WO-2013020995-A1 NEW ANTIBODIES AGAINST PHOSPHORYLCHOLINE ATHERA BIOTECHNOLOGIES AB (SE) 2013-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230310-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES IGLV6-57, VSIG8, IGSF11 LMNA 3639/4885AKT1 3142/4885ESR1 3488/4885
US-20180086847-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES IGLV6-57, VSIG8, IGSF11 LMNA 3639/4885AKT1 3142/4885ESR1 3488/4885
US-20140193413-A1 ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES IGLV6-57, VSIG8, IGSF11 LMNA 3909/4885AKT1 3330/4885ESR1 3906/4885
US-20210238311-A1 ANTIBODIES AGAINST PHOSPHORYLCHOLINE IGLV6-57, IGSF11, VSIG8 LMNA 3791/4885AKT1 3386/4885ESR1 3816/4885
US-20140178410-A1 ANTIBODIES AGAINST PHOSPHORYLCHOLINE IGLV6-57, IGSF11, VSIG8 LMNA 3791/4885AKT1 3386/4885ESR1 3816/4885
US-20180086848-A1 ANTIBODIES AGAINST PHOSPHORYLCHOLINE IGLV6-57, IGSF11, VSIG8 LMNA 3791/4885AKT1 3386/4885ESR1 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.